“The 31-GEP Stratifies Risk of Death in Patients with Stage I-IIA Cutaneous Melanoma: A SEER Real-World Evidence Study” (2025) SKIN The Journal of Cutaneous Medicine, 9(4), p. s586. doi:10.25251/ys9mt689.